UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 14, 2012

 

 

PSIVIDA CORP.

(Exact Name of Registrant as Specified in Its Charter)

 

 

 

Delaware   000-51122   26-2774444

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

400 Pleasant Street

Watertown, MA 02472

(Address of Principal Executive Offices) (Zip Code)

(617) 926-5000

(Registrant’s Telephone Number, Including Area Code)

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 5.07 Submission of Matters to a Vote of Security Holders.

The annual meeting of stockholders of pSivida Corp. (the “Company”) was held on December 14, 2012. The stockholders elected each of the Company’s nominees for director, approved the stock option grant to Dr. Ashton, approved the stock option grants to the Company’s non-executive directors, ratified the issuance of common stock and warrants in August 2012 and ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for fiscal year 2013. The proposals below are described in detail in the Company’s definitive proxy statement filed with the SEC on October 25, 2012.

The results are as follows:

 

1. Election of Directors.

 

DIRECTOR NOMINEE    FOR      WITHHELD      NON VOTE  

David J. Mazzo

     6,251,057         246,445         6,516,315   

Paul Ashton

     6,268,689         228,813         6,516,315   

Douglas Godshall

     6,242,057         255,445         6,516,315   

Paul A Hopper

     6,248,299         249,203         6,516,315   

Michael Rogers

     6,251,002         246,500         6,516,315   

Peter G. Savas

     5,716,049         781,453         6,516,315   

 

2. Approval of stock option grant to CEO Paul Ashton.

 

FOR

     5,386,929   

AGAINST

     1,083,693   

ABSTAIN

     26,880   

NON VOTES

     6,516,315   

 

3. Approval of stock option grants to the following non-executive directors.

 

DIRECTOR    FOR      AGAINST      ABSTAIN      NON VOTES  

Douglas Godshall

     5,170,574         1,302,427         24,501         6,516,315   

Paul A. Hopper

     5,170,566         1,304,302         22,634         6,516,315   

Michael Rogers

     5,183,324         1,289,677         24,501         6,516,315   

Peter G. Savas

     4,635,566         1,839,302         22,634         6,516,315   

David J. Mazzo

     5,171,576         1,303,140         22,786         6,516,315   

 

4. For purposes of ASX Listing Rule 7.4, to ratify the issuance and sale of 2,494,419 shares of common stock together with warrants to purchase 623,605 shares of common stock in August 2012.

 

FOR

     6,146,951   

AGAINST

     314,406   

ABSTAIN

     36,145   

NON VOTES

     6,516,315   


5. Ratification of the appointment of Deloitte & Touche LLP.

 

FOR

     12,877,719   

AGAINST

     132,834   

ABSTAIN

     3,264   


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

      PSIVIDA CORP.
Date: December 18, 2012     By:  

/s/ Lori Freedman

   

Lori Freedman, Vice President, Corporate Affairs,

General Counsel and Secretary